Organogenesis (ORGO) Announces Earnings Results

Organogenesis (NASDAQ:ORGO) posted its earnings results on Friday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05), Morningstar.com reports. The business had revenue of $57.12 million for the quarter, compared to analysts’ expectations of $55.12 million.

Organogenesis stock opened at $7.01 on Friday. Organogenesis has a 52-week low of $6.28 and a 52-week high of $310.90.

A number of research firms have issued reports on ORGO. BTIG Research began coverage on shares of Organogenesis in a research note on Friday, April 12th. They set a “buy” rating and a $12.00 target price for the company. Oppenheimer began coverage on shares of Organogenesis in a research note on Wednesday, April 17th. They set an “outperform” rating and a $11.00 target price for the company. Credit Suisse Group began coverage on shares of Organogenesis in a research note on Thursday, May 2nd. They set an “outperform” rating and a $9.00 target price for the company. CIBC began coverage on shares of Organogenesis in a research note on Wednesday, April 17th. They set an “outperform” rating and a $11.00 target price for the company. Finally, SunTrust Banks began coverage on shares of Organogenesis in a research note on Thursday, April 11th. They set a “buy” rating and a $11.00 target price for the company. Five research analysts have rated the stock with a buy rating, Organogenesis presently has an average rating of “Buy” and an average target price of $10.80.



A hedge fund recently bought a new stake in Organogenesis stock. California Public Employees Retirement System purchased a new position in Organogenesis Holdings Inc. (NASDAQ:ORGO) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 26,936 shares of the company’s stock, valued at approximately $202,000.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/05/12/organogenesis-orgo-announces-earnings-results.html.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Featured Story: What is the price-sales ratio?

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.